2020: Market Access Predictions in an Election Year
I’m Charline Shan, Vice President, Director – Access Experience Team, editor of All Access. I hope to bring you noteworthy and groundbreaking news via Precision’s bimonthly newsletter, by sharing the latest payer insights brought to you by our team of former payer decision-makers.
2020 holds a lot of uncertainties when it comes to the next big change in the US healthcare system. With the outcome of the presidential election at stake, the administration may stay the course and continue to push for price transparency and affordability, or change course and introduce no new proposals or legislation. In this edition, we asked our advisors for their predictions: Andy Cournoyer reflects on national payers, Dan Danielson determines how regional health plans respond to integration, Elizabeth Oyekan discusses a new focus for Medicare Advantage plan sponsors, and Jeremy Schafer assesses how pharmacy benefit managers (PBMs) will stay the same or change in 2020.
I think you’ll find the insights in All Access to be thought-provoking and helpful in navigating the payer landscape. As always, please feel free to drop me a note and let me know if you have a topic suggestion for the payer team to address, and we’ll do our best to cover it in a future edition.
Charline Shan, RPh, MPH
Vice President, Access Experience Team
All Access is a bimonthly newsletter that features key insights from our team of former payers, intended specifically for market access leaders. It is published by Precision for Value.
Manufacturer drug pricing has been and will continue to be a key focal point on political agendas. But as proposed legislation is blocked or stymied, will there be any room for advancement? Andy Cournoyer discusses potential roadblocks, opportunities for innovation, and what they mean for payers in 2020.
The current healthcare market is dominated by partnerships, mergers, and healthcare giants. Dan Danielson explores 2 examples of how smaller, regional health plans can stay in the mix and competitive with the big kids on the block.
Elizabeth Oyekan examines the increasingly influential role health plans play in the Medicare program, and their shift to focus on social determinants of health. What will new policy and structural changes mean to the plan benefits and offerings in the ever-changing healthcare landscape?
From the potential withdrawal of the rebate safe harbor, to the myriad state laws targeting various PBM practices, 2019 was a year of tumult for drug manufacturers and PBMs. Jeremy Schafer takes a look at how 2020 will stack up in comparison.